FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

Stock Down By 79.9%

 
• By Ayisha Sharma
hand throwing ball of paper into wastebasket
FibroGen Is Scrapping Another Phase III Trial In IPF After The Failure • Source: Shutterstock

More from Clinical Trials

More from R&D